Moffitt Cancer Center | Strategic Alliance Partners

December 18, 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

December 18, 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

December 10, 2024

Andrew Kuykendall, MD, discusses the advantages of treatment with momelotinib vs older-generation JAK inhibitors in myelofibrosis.

December 09, 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

December 02, 2024

Researchers at Moffitt Cancer Center published an article in Cancer Cell showing that necroptosis-mediated immune suppression occurs through release of IL-1α.

November 20, 2024

Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.

November 19, 2024

Richard Kim, MD, discusses the phase 3 CARES-310 trial evaluating rivoceranib plus camrelizumab in first-line hepatocellular carcinoma.

November 12, 2024

Tiago Biachi, MD, PhD, discusses the evolving role for surgery in colorectal cancer.

October 28, 2024

Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.

September 13, 2024

Joshua Linscott, MD, PhD, discusses the use of urinary cell-free tumor DNA for MRD detection prior to repeat resection in high-risk NMIBC.

September 11, 2024

Richard Kim, MD, discusses the safety of NT-17 and next steps for its evaluation in pretreated microsatellite stable CRC and PDAC.

September 10, 2024

Joshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.

September 09, 2024

Zanubrutinib was associated with lower treatment switching rates vs acalabrutinib and ibrutinib in real-world chronic lymphocytic leukemia.

August 30, 2024

Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.

August 29, 2024

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

August 27, 2024

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

August 23, 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.

August 22, 2024

Roger Li, MD, discusses the implications of a post hoc analysis of the KEYNOTE-057 trial in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.

August 19, 2024

Ahmad Tarhini, MD, PhD, discusses the hypothesis for investigating high-dose bolus IL-2 plus an anti–CTLA-4 agent in patients with advanced melanoma.

August 16, 2024

Ahmad Tarhini, MD, PhD, discusses the use of high-dose bolus IL-2 with ipilimumab followed by nivolumab in advanced melanoma following prior progression.